India's first Covid-19 vaccine update: Covaxin trial begins
With the rising number of novel coronavirus cases increasing at a pace of daily highs in the country, India's first indigenous Covid-19 vaccine Covaxin got a nod from the AIIMS Ethics Committee on Saturday to start human trials from Monday.
AIIMS-Delhi is among the 12 sites selected by the Indian Council for Medical Research (ICMR) for conducting phase I and II human trials of Covaxin. In phase I, the vaccine would be tested on 375 volunteers and a maximum of 100 of them would be from AIIMS.
Moreover, human dosing of the vaccine developed by Bharat Biotech India (BBIL) in collaboration with ICMR’s National Institute of Virology (NIV) also started on Wednesday, with the vaccine being given to participants at All India Institute of Medical Sciences, Patna and Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences (PGIMS) at Rohtak in Haryana, a spokesperson said in a statement on Friday, according to a Mint report.
The biotech company had got the nod for human clinical trials from the Drugs Controller General of India (DCGI) earlier this month.
